Perioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma.
Fiche publication
Date publication
janvier 2017
Journal
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe, Dr FEIN Francine, Mme JACQUIN Marion, Dr PAGET-BAILLY Sophie, Dr KIM Stephano, Dr LAKKIS Zaher
Tous les auteurs :
Kim S, Paget-Bailly S, Messager M, Nguyen T, Mathieu P, Lamfichekh N, Fein F, Fratté S, Cléau D, Lakkis Z, Jary M, Sakek N, Jacquin M, Foubert A, Bonnetain F, Mariette C, Fiteni F, Borg C
Lien Pubmed
Résumé
Even though the perioperative chemotherapy improves the overall survival (OS) compared to surgery alone in patients with a resectable gastroesophageal adenocarcinoma (GEA), prognosis of these patients remains poor. Docetaxel (D), cisplatin (C), and 5-fluorouracil (F) regimen improves OS compared to CF among patients with advanced GEA. We evaluated the potential interest of a perioperative DCF regimen, compared to standard (S) regimens, in resectable GEA patients.
Mots clés
Docetaxel, Gastric cancer, Gastroesophageal cancer, Neoadjuvant, Preoperative, Taxane
Référence
Eur J Surg Oncol. 2017 Jan;43(1):218-225